All News

#ACR21 #Abstr0690 Great work by @didemsayginmd et al. 2016 ACR-EULAR Myositis Response Criteria concurred with patient-reported outcomes (muscle disease activity, strength, pain, fatigue, physical function, quality of life and physical activity) @RheumNow https://t.co/IV3mAXKhbt https://t.co/GWC6IDcJSm

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Retrospective study of FAERS database: 186 irAE w/rheum manifestation 👉4.7% of all AEs 👉Arthritis, myositis, Sjogren, sarcoidosis were frequent 👉myositis assc w/ durvalumab, avelumab, atezolimumab and cemiplimab #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/t8UQWQicFc https://t.co/FGo6WCDQTp

Links:

TheDaoIndex KDAO2011 ( View Tweet)
KL-6, Anti-Ku, anti-CENPB were assoc'd w/ #myositis &/or ILD in #lupus patients accdg to this study by Dr. T Cotton et al. This may help identify patients at risk for developing such. @RheumNow #ACR21 abs0330 https://t.co/p0uxBOTLZm
sheila RHEUMarampa ( View Tweet)
In case you missed it…a popular read. Clinical Associations with Myositis Antibodies Read the full article on #RheumNow https://t.co/tzPU1scc8x https://t.co/pmmtmIuz31

Links:

Dr. John Cush RheumNow ( View Tweet)
Clinical Associations with Myositis Antibodies Read the full post on #RheumNow https://t.co/tzPU1scc8x https://t.co/F537tPAQTU

Links:

Dr. John Cush RheumNow ( View Tweet)
antisynthetase,myositis,nail,erythema

Clinical Associations with Myositis Antibodies

d Jack Cush, MD

While myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) may have prognostic value through their clinical associations, many patients will not have them and overall, they are poorly predictive of a malignancy risk. 

Read Article
ICYMI: JAK inhibitors as potential treatment for Juvenile Dermatomyositis: nice review of the biology of JAKi effects and the reports of JAKi success in adults and kids with IIM https://t.co/k3qunsCdBN https://t.co/nyqMo6vh88

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

RheumNow Podcast – Jack of All Subspecialties (10.1.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
RheumNow Podcast square

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

d Jack Cush, MD

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID breakthrough infections, and statin use and the risk of RA, as I review the news and journal articles from the past week on RheumNow.

Read Article
arm,muscle,weak

High Comorbidity Rates with Inclusion Body Myositis

d Jack Cush, MD

Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated.

Read Article
infection pneumonia

Pneumocystis Often Lethal in Dermatomyositis

d MedPage Today

Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.

Read Article
RheumNow Podcast square

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

d Jack Cush, MD

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article
J Hopkins study of 524 myositis-specific Ab positive pts shows that while 91% met 2017 EULAR/ACR criteria for Dx of myositis, 20% of HMGCR+ & 50% anti-PL7 did not classify as myositis; ~10% anti-SRP & HMGCR were dx as inclusion body myositis https://t.co/jcIn6SzbGG

Links:

Dr. John Cush RheumNow ( View Tweet)

Differential Dx of immune-mediated necrotizing myopathies (IMNM) - HMGCR & Signal recognition particle Abs; checkpoint inhibitors, anti-Mi2 dermatomyositis, antisynthetase syndr. antimitochondrial Abs, GVHD, SARS-CoV-2 infection https://t.co/hhizx5gAet

Links:

Dr. John Cush RheumNow ( View Tweet)

Popular on RheumNow https://t.co/BZsl8a6ArW The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/RNFsJadUZx

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Skin Involvement with HMGCR Necrotizing Myositis The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, more so than previously reported. https://t.co/RR07dYIJSr https://t.co/MiaIqvMPaB

Links:

Dr. John Cush RheumNow ( View Tweet)
myositis, polymyositis, wikipedia

Skin Involvement with HMGCR Necrotizing Myositis

d Jack Cush, MD

The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, moreso than previously reported.

Read Article
204 pts w/ dermatomyositis/polymyositis Rx w/ IV early pulse steroids(IVMP) or IVIG. IVMP & IVMP+IVIG was assoc w/ 56-58% incr odds of complete response. Pulse IVMP+IVIG incr risk of steroid D/C. Early IVMP/IVIG=no impact on mortality https://t.co/yRFJgos8Qq

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: FDA Approves IVIG in Dermatomyositis https://t.co/BZsl8a6ArW The FDA has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/VFF0QMqbin

Links:

Dr. John Cush RheumNow ( View Tweet)
Jo1.gottrons.jpg

FDA Approves IVIG in Dermatomyositis

d Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).

Read Article

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.